Systemtherapie des metastasierten Tumors des oberen HarntraktesSystemic treatment of metastatic tumors of the upper urinary tract

被引：0
|
作者：
C. Darr
B. A. Hadaschik
S. Tschirdewahn
机构：
[1] Universitätsmedizin Essen,Klinik und Poliklinik für Urologie, Kinderurologie und Uroonkologie
来源：
Der Urologe | 2019年 / 58卷 / 1期
关键词：
Urothelkarzinom; Chemotherapie; Immuntherapie; Harnblasenkarzinom; Gemcitabin; Urothelial carcinoma; Chemotherapy; Immunotherapy; Bladder cancer; Gemcitabin;
D O I：
10.1007/s00120-018-0835-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：30 / 33
页数：3
相关论文
共 50 条
  • [41] Systemische Behandlung des metastasierten NierenzellkarzinomsParadigmenwechsel nach Einführung der zielgerichteten TherapieSystemic treatment of metastatic renal cell carcinomaChange of paradigms after introduction of targeted therapy
    P. Papavassilis
    L.M. Krabbe
    B. Thielen
    M. Bögemann
    R. Moritz
    I. Hoffmeister
    L. Hertle
    E. Herrmann
    Der Urologe, 2014, 53 (4): : 531 - 536
  • [42] Paradigmenwechsel in der Systemtherapie des metastasierten Urothelkarzinoms – Antikörper-Wirkstoff-Konjugate (ADC) und FGFR-Inhibitoren („fibroblast growth factor rezeptor“)Paradigm shift in systemic therapy for metastatic urothelial carcinoma—antibody–drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors
    Jozefina Casuscelli
    Gunhild von Amsberg
    Margitta Retz
    best practice onkologie, 2024, 19 (11) : 470 - 479
  • [43] Paradigmenwechsel in der Systemtherapie des metastasierten Urothelkarzinoms – Antikörper-Wirkstoff-Konjugate (ADC) und FGFR-Inhibitoren („fibroblast growth factor rezeptor“)Paradigm shift in systemic therapy for metastatic urothelial carcinoma—antibody–drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors
    Jozefina Casuscelli
    Gunhild von Amsberg
    Margitta Retz
    Die Urologie, 2024, 63 (10) : 1002 - 1010
  • [44] Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas: A Systematic Review and Meta-Analysis
    Fang, Dong
    Li, Xue-Song
    Xiong, Geng-Yan
    Yao, Lin
    He, Zhi-Song
    Zhou, Li-Qun
    UROLOGIA INTERNATIONALIS, 2013, 91 (03) : 291 - 296
  • [45] Analysis of the impact on the overall survival of laparoscopic Vs open nephroureterectomy in locally advanced upper tract urinary tumors (pT3-pT4)
    Garcia, David
    Lacarra Fernandez, Seila
    Asiain, Micaela
    Montesino, Manuel
    ARCHIVOS ESPANOLES DE UROLOGIA, 2020, 73 (03): : 183 - 191
  • [46] Resection of the Intramural Portion of the Distal Ureter during Transurethral Resection of Bladder Tumors: Predictive Factors for Secondary Stenosis and Development of Upper Urinary Tract Recurrence
    Rodriguez Faba, Oscar
    Gaya, J. M.
    Breda, Alberto
    Juarez del Dago, Pablo
    Pisano, Francesca
    Salas, Daniel
    Palou, Juan
    JOURNAL OF UROLOGY, 2016, 196 (01) : 52 - 56
  • [47] Prevention of Recurrent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: An Individualized Selection Strategy Based on Patient Risk Stratification Is Needed
    Long, Xingbo
    Qi, Lin
    Zu, Xiongbing
    Li, Yuan
    He, Wei
    Pi, Shuohuang
    Chen, Xiang
    Zhou, Kebing
    Hu, Xiheng
    Chen, Minfeng
    UROLOGIA INTERNATIONALIS, 2017, 98 (03) : 312 - 319
  • [48] In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors
    Enis Coskuner
    Ibrahim Cevik
    Alp Ozkan
    Ozdal Dillioglugil
    Atıf Akdas
    International Urology and Nephrology, 2012, 44 : 793 - 798
  • [49] In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors
    Coskuner, Enis
    Cevik, Ibrahim
    Ozkan, Alp
    Dillioglugil, Ozdal
    Akdas, Atif
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2012, 44 (03) : 793 - 798
  • [50] „Second-line-Polychemotherapie“ beim metastasierten Urothelkarzinom des NierenbeckensAndauernde partielle Remission nach 18 Kursen Gemcitabin/Paclitaxel trotz 24 Kursen Gemcitabin/Cisplatin im „stable disease““Second line” polychemotherapy in metastatic urothelial cancer of the renal pelvisPersisting partial remission by 18 treatment cycles of Gemcitabine/Paclitaxel after 24 treatment cycles Gemcitabine/Cisplatin “stable disease”
    A. Bannowsky
    B. Wefer
    M. Naumann
    M. Hamann
    S. Hautmann
    K.-P. Jünemann
    Der Urologe, 2005, 44 : 915 - 917
12345